Vascular risk screening and management after late-onset seizures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project uses a cluster design in which participating clinics adopt routine vascular risk factor screening (blood pressure, medical history, BMI, and laboratory tests) for patients with new-onset unprovoked seizures after age 50. It has two linked components: a prospective single-group observational cohort where screened patients are followed for one year to document risk-factor management and short-term outcomes, and a register-based cohort comparing all patients at participating sites to historical controls with at least 5 (likely 10) years of follow-up. The register study will use time-to-event analyses (Kaplan–Meier) to detect differences in long-term cardiovascular events at the system level. The combined approach aims to show whether implementing routine vascular risk assessment in this population changes patient care and long-term cardiovascular morbidity.

Why it matters

Who can join: the full rules

Inclusion Criteria

Clinical study:

\- First assessment for unprovoked seizures or epilepsy with onset after age 50 -- - vascular risk factor evaluation per the new routine at participating care givers

Register study:

* age ≥50 with a first-ever outpatient appointment to one of the participating clinics and
* a first-listed diagnostic code for seizures or epilepsy (ICD-10: R568, G40)

Exclusion Criteria

Clinical study:

* Inability to consent.
* Progressive brain disease (tumour or degenerative)

Register study:

* preexisting seizures/epilepsy, as demonstrated by a registered diagnostic code for seizures (ICD-10: R568, G40, G41) or a dispensed antiseizure medication (ATC-code: N03) more than 3 months before the initial consultation
* a registered diagnostic code for stroke or TIA (ICD-10: I61, I63, I64, or G45 except G454) before the initial consultation, or
* progressive brain disease, as indicated by diagnostic codes or drug prescriptions suggestive of brain tumors (ICD-10: C71, D33, D43, C793) or
* neurocognitive disorders (ICD-10: F00-F03, F051, G30, G318, G912; ATC code: N06D).

Where it's running

• Södra Älvsborg Sjukhus
  Borås, Sweden Recruiting
• Salgrenska University Hospital
  Gothenburg, Sweden Recruiting
• Skånes universitetssjukhus
  Malmö, Sweden Recruiting

Study contacts

• Study coordinator: Johan Zelano, MD PhD
• Email: johan.zelano@neuro.gu.se
• Phone: +46313421000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-personalized Medilepsy app to help teens and young adults with epilepsy manage medicines and transition to adult care

  This trial tests whether an AI-personalized Medilepsy app helps underserved adolescents and young adults with epilepsy (ages 14–24) take their anti-seizure medicines and prepare for adult care better than the standard app.

  Recruiting at 2 sites University of Central Florida · Orlando, Florida and 1 other locations · NCT07445074

• Project PENGUIN: Profiling phenotypic, epigenetic, and neurogenetic traits in rare neurodevelopmental disorders

  This project will try to collect clinical data, genetic and epigenetic samples, imaging, and skin-derived cell models from people with rare neurogenetic disorders like SYT1/BAGOS to help track disease and support future treatments.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07329257

• Long-term RAP-219 treatment for adults with focal onset seizures

  This trial will try RAP-219, an investigational anti-seizure medication, in adults with refractory focal seizures to see if it is safe long-term and helps reduce seizures.

  Recruiting at 7 sites Phase 2 Rapport Therapeutics Inc. · Boise, Idaho and 6 other locations · NCT07219407

• Detecting thalamus seizures using a Percept deep brain stimulator

  This project will test whether the Medtronic Percept DBS device can reliably detect seizures from the thalamus in adults with drug-resistant epilepsy.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06700356

• Optimizing brain stimulation for epilepsy treatment

  This study is testing whether low or high frequency brain stimulation can help people with epilepsy control their seizures better.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06617845

• Low-intensity focused ultrasound treatment for drug-resistant epilepsy

  This study is testing if low-intensity focused ultrasound can help people with drug-resistant temporal lobe epilepsy have fewer seizures while they continue taking their regular medications.

  Recruiting at 3 sites Phase 1/2 NaviFUS Corporation · Palo Alto, California and 2 other locations · NCT06388707

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.